The primary goal of a pediatric liver transplant is to restore normal hepatic metabolic, synthetic, and excretory function in pediatric patients suffering from irreversible liver failure. The liver performs critical biological processes including protein synthesis, blood clotting factor production, bilirubin excretion, toxin clearance, and nutrient metabolism. When chronic severe intrahepatic cholestasis, cirrhosis, or acute liver cell death impairs these functions, liver transplantation becomes necessary to prevent fatal multi-organ failure and enable normal child growth and development. The field falls under pediatric transplant hepatology and pediatric transplant surgery.

The pediatric liver transplant procedure consists of three surgical phases: recipient hepatectomy, the anhepatic phase, and graft implantation with vascular and biliary reconstruction. Under general anesthesia, a subcostal abdominal incision (Mercedes-Benz or L-shaped) is made. The native diseased liver is dissected free from surrounding tissue and its major blood vessels. In the anhepatic phase, the diseased liver is removed by clamping and dividing the portal vein, hepatic artery, common bile duct, and retrohepatic inferior vena cava (or preserving the cava using the piggyback technique). The healthy donor liver graft (whole organ, split liver segment, or living donor left lateral segment) is placed into the abdominal cavity. Sequential vascular connections (anastomoses) are performed: hepatic vein or caval connection, portal vein connection, and microscopic hepatic artery connection using surgical loupes or operating microscopes. After restoring blood flow to the graft (reperfusion), biliary continuity is established, typically via a Roux-en-Y choledochojejunostomy connecting the donor bile duct to a loop of the child's small intestine. Abdominal drains are placed, and the abdominal incision is closed in layers.

Evidence-based clinical advantages of pediatric liver transplantation include:

• Curative Restoration of Hepatic Function: Reverses severe jaundice, hepatic encephalopathy, bleeding disorders, and abdominal fluid accumulation.
• Correction of Metabolic Defects: Directly replaces missing hepatic enzymes in genetic metabolic disorders, preventing irreversible neurological and organ damage.
• Reversal of Growth Failure: Restores normal growth hormone signalling and nutrient absorption, enabling significant catch-up growth in infants and children (SPLIT Registry, 2020).
• High Long-Term Patient Survival: Five-year overall patient survival rates exceed 85% to 90%, and 10-year survival rates approximate 80% to 85% under modern protocols (OPTN/UNOS Data, 2023).
• Improved Quality of Life: Resolves severe itching (pruritus) in cholestatic liver diseases, enabling normal school attendance and physical activity.

Recovery occurs in several structured clinical phases:

• Immediate Postoperative Phase (Days 1–7): Intensive monitoring in the PICU focusing on graft vascular patency via serial Doppler ultrasound, fluid balance, breathing support, and intravenous immunosuppression.
• Intermediate Hospital Phase (Weeks 2–3): Transition to the pediatric transplant ward, conversion to oral immunosuppressive medications, nutritional advancement, surgical drain removal, and extensive parent training.
• Early Outpatient Recovery (Months 1–3): Frequent clinic visits (1–3 times weekly) for blood tests monitoring liver enzymes, kidney function, and drug levels. Infection prophylaxis continues.
• Long-Term Maintenance (Beyond 6 Months): Tapering immunosuppression to stable maintenance doses, routine outpatient laboratory monitoring, return to school, non-live pediatric immunizations, and long-term growth tracking.

Pediatric liver transplantation treats a broad spectrum of acute and chronic liver conditions in children:

• Biliary Atresia: A congenital blockage of the bile ducts and the most common indication for pediatric liver transplantation, accounting for 40% to 50% of pediatric recipients (AASLD/AST Guidelines, 2022).
• Metabolic Liver Diseases: Inherited metabolic errors including alpha-1 antitrypsin deficiency, Wilson disease, tyrosinemia type 1, glycogen storage diseases, progressive familial intrahepatic cholestasis (PFIC), and urea cycle defects.
• Pediatric Acute Liver Failure (PALF): Rapid destruction of liver tissue resulting from viral hepatitis, drug toxicity, metabolic crises, or autoimmune responses.
• Cirrhosis and Autoimmune Liver Conditions: Progressive scarring from autoimmune hepatitis, primary sclerosing cholangitis, or cryptogenic liver disease.
• Pediatric Hepatic Tumors: Primary malignant liver tumors unsuitable for surgical resection, primarily hepatoblastoma and select cases of hepatocellular carcinoma.

Preparation for a pediatric liver transplant involves a multi-system diagnostic evaluation and optimized medical stabilization. Pre-transplant evaluations include complete blood counts, coagulation profiles, hepatic function tests, viral serologies (CMV, EBV, HIV, Hepatitis B/C, Varicella), ABO blood typing, and tissue typing. Physiological testing includes echocardiography, chest radiographs, abdominal Doppler ultrasound or CT/MRI angiography, and formal neurodevelopmental assessments. Nutritional support is prioritized; malnourished infants and children receive specialized high-calorie, medium-chain triglyceride (MCT) formulas or enteral tube feedings to treat muscle wasting and growth delay. Required non-live pediatric immunizations are updated, and live vaccines (varicella, MMR) are administered at least 4 to 6 weeks prior to transplantation when feasible. Caregivers participate in comprehensive educational sessions covering medication schedules, infection control strategies, and long-term care plans.

Complications following pediatric liver transplantation are categorized by severity and clinical timing. Common/Mild: Temporary surgical pain, transient fluid retention, mild hypertension secondary to calcineurin inhibitor drugs, and temporary liver enzyme elevations during medication adjustments. Moderate/Uncommon: Surgical site infection, pleural effusion, delayed graft function, acute cellular rejection (occurring in 30% to 40% of recipients, managed with pulse corticosteroids), biliary stricture or bile leak, and viral reactivation (CMV or EBV). Severe/Rare: Hepatic artery thrombosis (HAT, occurring in 5% to 10% of pediatric cases, requiring urgent thrombectomy, revascularization, or re-transplantation), portal vein thrombosis, primary graft non-function, severe hyperacute rejection, post-transplant lymphoproliferative disorder (PTLD, strongly associated with primary EBV infection), severe systemic sepsis, and patient death.

The clinical journey begins with a comprehensive multi-disciplinary evaluation by pediatric hepatologists, transplant surgeons, cardiologists, pulmonologists, infectious disease specialists, clinical social workers, and dietitians. Once deemed eligible, the child is listed on the national organ registry using the Pediatric End-Stage Liver Disease (PELD) or Model for End-Stage Liver Disease (MELD) score, or evaluated for a living donor liver transplantation (LDLT). During surgery, the recipient undergoes native hepatectomy followed by vascular anastomoses (hepatic vein, portal vein, hepatic artery) and biliary reconstruction (typically a Roux-en-Y choledochojejunostomy). Postoperatively, the child is monitored in a pediatric intensive care unit (PICU) to manage blood pressure, graft perfusion, immunosuppression (typically calcineurin inhibitors), and infection prophylaxis. Long-term care involves lifetime immunosuppression, growth monitoring, and regular lab work.